Intracranial Tumor Clinical Trial
— INVIVOOfficial title:
Comparison of Fluorescein-INtra-VItal Microscopy Versus Conventional Frozen Section Diagnosis for intraOperative Histopathological Evaluation (INVIVO)
Verified date | April 2022 |
Source | Technical University of Munich |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
With the appliance of the in-vivo microscopy after Fluorescein staining, the investigators hypothesize that the preliminary in-vivo histopathological diagnostic accuracy is not inferior to conventional frozen section analysis accuracy when using the final histopathological result as gold standard.
Status | Completed |
Enrollment | 210 |
Est. completion date | August 3, 2022 |
Est. primary completion date | June 17, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Age =18 years 2. Signed informed consent 3. Suspected intracranial tumor revealed by cranial magnetic resonance imaging (according to clinical routine) scheduled for resection with intraoperative frozen section evaluation Exclusion Criteria: 1. Known allergic or suspected allergic reactions to fluorescein sodium 2. Liver disease, CHILD B or C 3. Patients under medication with beta-blockers, digoxin, chinidin and probenecid as well as inhibitors of glucuronidation, such as immunosuppressants, when the medication must not be discontinued perioperatively 4. Patients with relevant congenital limitations of glucuronidation performance (e.g. Rotor syndrome, Gilbert-Meulengracht syndrome, Crigler-Najjar syndrome) 5. Patients with terminal renal failure requiring hemodialysis 6. Inability to provide informed consent 7. Pregnancy (incl. positive pregnancy test) 8. Women of childbearing age must be non-lactating and surgically sterile or using a highly effective method of birth control and have a negative pregnancy test. Acceptable methods of birth control with a low failure rate (i.e. less than 1% per year) when used consistently and correct are such as implants, injectables, combined oral contraceptives, hormonal intrauterine devices (IUDs), sexual abstinence or vasectomized partner. |
Country | Name | City | State |
---|---|---|---|
Germany | Universitätsklinikum Mannheim | Mannheim | |
Germany | Technische Universität München, Klinik und Poliklinik für Neurochirurgie | München | |
Germany | Universitätsklinikum Regensburg | Regensburg |
Lead Sponsor | Collaborator |
---|---|
Technical University of Munich | Carl Zeiss Meditec AG |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Significance: The diagnostic accuracies of the individual methods used for preliminary intraoperative histopathological diagnosis (D1:fluorescein sodium with in-vivo microscopy versus D2: preliminary frozen section assessment) | The primary objective of the clinical trial is to compare the significance of intravenously applied fluorescein as staining agent for assessment of brain tissue texture via in-vivo confocal microscopy with the conventional intraoperative histological frozen section analysis of identical brain tissue samples in the same patient. Both methods will be compared in terms of their accuracy using the standard of practice, the final pathological diagnosis (immunochemistry/molecular pathology). | 14 days | |
Secondary | Incidence of adverse events during surgery and until end of follow-up period (Safety Assessment) | To assess the safety of the Investigational Medicinal Product (IMP) as staining agent for in-vivo confocal microscopy by documentation of adverse events during surgery and until end of follow-up period. | 24 days | |
Secondary | Analysis of surgical time span (comparison of the time span to conduct the assessment of brain tissue texture with fluorescein intervention with the time span to conduct assessment of conventional intraoperative frozen section intervention. | Analysis of surgical time span: comparison of the time span to conduct the assessment of brain tissue texture with fluorescein intervention with the time span to conduct assessment of conventional intraoperative frozen section intervention. | 14 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01674582 -
Treatment Effects Inclusive Cognitive Impact and Possibilities to Individually Adjusted Treatment in Patients With Intracranial Tumors With Clinical, Neuropsychological and Imaging Parameters
|
N/A | |
Completed |
NCT00936806 -
Observational Study of the Differences in Characteristics of the Spontaneous Electroencephalogram, Derived From the Left and Right Hemisphere in Patients With Unilateral Intracranial Tumor During Routine Anesthesia: Comparison With a Control Group Without Intracranial Pathology
|
N/A | |
Completed |
NCT03123302 -
Our Anesthesia Experience During MRI Scan
|
||
Not yet recruiting |
NCT06362304 -
99mTc-CNDG SPECT/CT in Brain Tumors
|
N/A |